At BBK we’re often talking about adaptive recruitment and the importance of modifying traditional approaches to increase patient enrollment and retention. Developing an overarching branding strategy for a clinical trial is one of the first steps in a patient recruitment campaign and it’s not a one size fits all approach. BBK has worked on thousands of campaigns over the years, many of which target patients in various countries. There is a lot of diversity to consider when developing the right clinical study branding strategy. Multiple languages, differing philosophies on sensitive topics that may be taboo to discuss publicly in some countries, and varying regulatory environments mean branding must take a strategic and thoughtful approach.
The global operating environment for trials continues to become more competitive and complex. As a result, demand for new approaches and solutions to improve site engagement and patient enrollment has increased dramatically. Remaining at the top of the list, among the many other challenges sponsors face today is making sure sites have real-time access to the right study information and materials. Despite today’s increasingly competitive landscape, when the study community has what it needs to be and stay informed, the right patients enroll, and enrollment happens on schedule.
Members of the BBK Worldwide team periodically attend industry events throughout the year. We love to network and learn from our peers, and when we are invited to speak we jump at the opportunity to bring our own expertise to the table and join in the conversation.
For patient recruitment and engagement in clinical trials, mHealth is a minimum requirement to reach and connect with patients in today’s mobile-centric world. BBK Worldwide is excited to host a panel discussion with experts from Oracle and health wearables start-up Empatica on Thursday, April 16th at 2:00pm EST where panelists will highlight real-world examples that successfully blend technology with patient centricity – the right combination that drives mHealth delivery from theory to reality.
Early last week Apple excited many and rattled others with its ResearchKit announcement. The open-source toolkit or “framework” includes disease-specific applications that patients can use to track their symptoms, and will allow researchers to gather data from iPhone users to help further medical research. While reaction has been mixed, most agree that tools that help medical science advance and make people and patients more involved are welcome innovations. But clinical research and medical research aren’t the same. Running a global clinical trial is much different than creating and delivering apps to aid research on a particular disease.
You know the feeling. You believe strongly in an idea that hasn’t yet hit the mainstream. You talk it up, write about it, join a march, advocate for it, and sometimes even beg people to give the concept a try. So here we are. Patient centricity in clinical research has hit the mainstream. There is no conference that doesn’t include the topic on the agenda – and many have absorbed it into their meeting titles and promotional materials. No group of clinical trial professionals gets around a table or on a conference call without at least three people using the phrase “patient centric” during the discussion. Some companies even require that clinical teams incorporate patient centricity into their study design. Great progress, you say.
Topics: Patient Centricity
BBK Worldwide is pleased to offer our first “Focus 5”, a compilation of quick tips, advice and insights to help companies understand patient centricity as it relates to enhanced patient recruitment and patient engagement within clinical trials.
The 2015 annual SCOPE Summit for Clinical Ops Executives was a tremendous success. It was great to see some of the clinical trial industry’s elite presenting on some amazing initiatives to raise awareness of clinical research. In thinking about all of the collaborative discussions that took place at the conference this year (and there were many), the following are three key takeaways that represent an exciting future for patient centricity within the clinical research industry.
Since BBK Worldwide began in 1983, we’ve conducted thousands of clinical trial marketing and advertising campaigns on behalf of our clients in the pharmaceutical, biotechnology and medical device industries. Three decades of experience in any industry will see trends come and go, and offer much perspective into what works and what doesn’t. While the tactics may shift, there is one constant – a solid message.
Today is Rare Disease Day. Launched by EURORDIS and its Council of National Alliances in 2008, this annual event has grown to include a record-breaking 84 countries from around the world that have come together to raise awareness among the general public and decision makers about rare disease and its impact on the lives of patients.